T1	intervention 120 162	high-intensity interval endurance training
T2	control 916 977	placebo-intervention (supervised myofascial release training)
T3	duration 1102 1113	12-18Â weeks
T4	No-of-participants 1115 1125	Fifty-nine
T5	eligibility 1126 1150	women with breast cancer
T6	outcome-Measure 1434 1456	cognitive test battery
T7	outcome-Measure 1825 2453	Go-/No-Go test performance (response inhibition), self-perceived cognitive functioning, serum levels of pro- and antiinflammatory markers (tumor necrosis factor alpha, Interleukin-6, Interleukin-1 alpha, Interleukin-1 beta, C-reactive protein, Interleukin-1 receptor antagonist and Interleukin-10), serum levels of neurotrophic and growth factors (brain-derived neurotrophic factor, insulin-like growth factor 1 and vascular endothelial growth factor), as well as common cancer-related side effects (decrease in physical capacity, fatigue, anxiety and depression, sleep disturbances, quality of life and chemotherapy compliance)
